Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
10x Genomics, Inc. is a life sciences technology company that develops and sells instruments, consumables, and software for high-resolution analysis of biological systems at the single-cell and spatial level. The company operates within the biotechnology, genomics, and life sciences research tools industries, primarily serving academic researchers, pharmaceutical and biotechnology companies, and translational research institutions. Its core value proposition is enabling scientists to analyze gene expression, immune profiling, epigenetics, and tissue architecture with high throughput and precision.
The company’s primary revenue drivers are the sale of proprietary consumables used with its instruments, complemented by instrument sales and software offerings. 10x Genomics is known for its Chromium single-cell platform and Visium spatial transcriptomics platform, which are widely adopted in basic research and drug discovery. Founded in 2012, the company emerged from stealth with a focus on solving technical limitations in single-cell analysis and completed its initial public offering in 2019, significantly expanding its global commercial footprint and R&D investments.
Business Operations
10x Genomics generates revenue through two main operating segments: Single Cell and Spatial Biology. The Single Cell segment includes the Chromium platform, associated reagents, and consumables that enable single-cell gene expression, immune profiling, and multiomic analysis. The Spatial Biology segment centers on the Visium platform and related consumables, allowing researchers to map gene expression within intact tissue sections. Consumables represent the majority of recurring revenue, reflecting a razor-and-blade business model.
Operations are global, with sales distributed across North America, Europe, and Asia-Pacific. The company controls proprietary microfluidics technology, chemistry, and bioinformatics software that integrate across its platforms. 10x Genomics operates primarily through wholly owned subsidiaries and does not rely heavily on joint ventures, instead maintaining direct sales, marketing, and support capabilities in key markets to serve research institutions and biopharmaceutical customers.
Strategic Position & Investments
Strategically, 10x Genomics focuses on expanding its platform ecosystem, increasing consumables adoption, and extending its technologies into new biological applications. Growth initiatives include advancing multiomic capabilities, improving spatial resolution, and scaling throughput for large population-level studies. The company invests heavily in internal research and development to maintain technological differentiation in single-cell and spatial analysis.
Notable strategic investments include acquisitions aimed at strengthening spatial biology and in situ analysis capabilities, most prominently ReadCoor, Inc., which contributed technology foundational to the Visium platform. The company continues to invest in emerging areas such as in situ gene expression, protein detection, and integrated multiomic workflows, positioning itself at the intersection of genomics, imaging, and computational biology.
Geographic Footprint
10x Genomics is headquartered in Pleasanton, California, and operates across North America, Europe, and Asia-Pacific. The United States represents its largest market, driven by strong demand from academic research institutions and biotechnology companies. Europe is a significant secondary market, supported by direct commercial operations and distributor networks.
Internationally, the company has established a presence in key research hubs, including Western Europe, China, Japan, and South Korea, reflecting the global nature of genomics research. Its geographic diversification supports both revenue growth and resilience, while ongoing investments in international sales and support infrastructure expand its influence in emerging life sciences markets.
Leadership & Governance
10x Genomics was co-founded by Serge Saxonov, who has played a central role in shaping the company’s scientific and strategic direction. The leadership team emphasizes long-term innovation, disciplined investment in R&D, and close collaboration with the scientific community to drive adoption of its platforms.
Key executives include:
- Serge Saxonov – Chief Executive Officer and Co-Founder
- Ben Hindson – Chief Scientific Officer and Co-Founder
- Dan Malarek – Chief Financial Officer
- Eric S. Whitaker – Chief Commercial Officer
- Yannick Monsellier – Chief Operating Officer
The governance structure reflects a balance between scientific leadership and operational execution, with a strategic vision centered on advancing biological discovery through scalable, high-resolution genomic technologies.